Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial

GlobeNewswire March 19, 2014

Anavex Announces $10 Million Private Placement of Convertible Debentures

GlobeNewswire March 13, 2014

Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)

GlobeNewswire March 10, 2014

Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists

GlobeNewswire March 4, 2014

Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds

GlobeNewswire February 26, 2014

Anavex to Present at 16th Annual BIO CEO & Investor Conference

Globe Newswire February 3, 2014

Sigma-1 receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases - Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases

Globe Newswire January 23, 2014

Anavex Agreement With The Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS

Globe Newswire January 13, 2014

Anavex CEO Invited to Present at Upcoming Investment Conferences

Globe Newswire January 7, 2014

Anavex Appoints Clinical Design Expert to Scientific Advisory Board

Globe Newswire December 10, 2013

Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board

PR Newswire December 3, 2013

Anavex Announces Expansion of Scientific Advisory Board

PR Newswire November 20, 2013

Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of Alzheimer's Disease

PR Newswire November 18, 2013

Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer's Disease

PR Newswire November 12, 2013

Anavex reports ANAVEX 2-73 blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of Alzheimer's Disease

PR Newswire November 4, 2013

Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting

PR Newswire October 29, 2013

Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer's Disease

Marketwired October 22, 2013

Anavex comments on newly released World Alzheimer Report 2013

PR Newswire September 23, 2013

Anavex to present at upcoming Rodman & Renshaw Annual Global Investment Conference in New York

PR Newswire September 3, 2013

Anavex CEO writes letter to shareholders

PR Newswire August 15, 2013